Cargando…
Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy
PURPOSE: The aim of this study is to evaluate long-term treatment outcome and toxicities among vestibular schwannoma (VS) patients treated with hypofractionated stereotactic radiotherapy (HSRT). METHODS: 383 patients with unilateral VS treated with HSRT (25 Gy, five fractions) between 1995 and 2007...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591320/ https://www.ncbi.nlm.nih.gov/pubmed/28929084 http://dx.doi.org/10.3389/fonc.2017.00200 |
_version_ | 1783262689868382208 |
---|---|
author | Patel, Mira A. Marciscano, Ariel E. Hu, Chen Jusué-Torres, Ignacio Garg, Rupen Rashid, Arif Francis, Howard W. Lim, Michael Redmond, Kristin J. Rigamonti, Daniele Kleinberg, Lawrence R. |
author_facet | Patel, Mira A. Marciscano, Ariel E. Hu, Chen Jusué-Torres, Ignacio Garg, Rupen Rashid, Arif Francis, Howard W. Lim, Michael Redmond, Kristin J. Rigamonti, Daniele Kleinberg, Lawrence R. |
author_sort | Patel, Mira A. |
collection | PubMed |
description | PURPOSE: The aim of this study is to evaluate long-term treatment outcome and toxicities among vestibular schwannoma (VS) patients treated with hypofractionated stereotactic radiotherapy (HSRT). METHODS: 383 patients with unilateral VS treated with HSRT (25 Gy, five fractions) between 1995 and 2007 were retrospectively reviewed. Treatment failure was defined as requiring salvage microsurgery. Posttreatment new/progressive clinical symptoms or increases in baseline tumor volume (BTV) due to treatment effect or progression were noted. Symptom outcomes were reported as baseline and posttreatment ± improvement, respectively. Symptoms were grouped by cranial nerve (CN) VII or CNVIII. Audiometry was assessed baseline and posttreatment hearing. Patients were grouped as having greater than serviceable hearing [Gardner Robertson (GR) score 1–2] or less than non-serviceable hearing (GR score 3–5) by audiometry. RESULTS: Median follow-up was 72.0 months. Nine (2.3%) experienced treatment failure. At last follow-up, 74 (19.3%) had new/progressive symptoms and were categorized as radiologic non-responders, whereas 300 (78.3%) had no tumor progression and were grouped as radiologic responders. Average pretreatment BTV for treatment failures, radiologic non-responders, and radiologic responders was 2.11, 0.44, and 1.87 cm(3), respectively. Pretreatment CNVII and CNVIII symptoms were present in 9.4 and 93.4% of patients, respectively. Eight (24%) with pre-HSRT CNVII and 37 (10%) with pre-HSRT CNVIII symptoms recovered CN function post-HSRT. Thirty-five (9%) and 36 (9.4%) experienced new CNVII and CNVIII deficit, respectively, after HSRT. Of these, 20 (57%) and 18 (50%) recovered CNVII and CNVIII function, respectively, after HSRT. Evaluable audiograms were available in 199 patients. At baseline and at last follow-up, 65.8 and 36.2% had serviceable hearing, respectively. Fifty-one percent had preservation of serviceable hearing at last follow-up. CONCLUSION: Treatment of VS with HSRT is effective with treatment success in 97.7% and an acceptable toxicity profile. Less than one-third of patients experience any new CNVII or CNVIII deficit posttreatment. Greater than 50% of patients with serviceable hearing at baseline maintained hearing function. Improved methods to differentiate treatment effect and tumor progression are needed. |
format | Online Article Text |
id | pubmed-5591320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55913202017-09-19 Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy Patel, Mira A. Marciscano, Ariel E. Hu, Chen Jusué-Torres, Ignacio Garg, Rupen Rashid, Arif Francis, Howard W. Lim, Michael Redmond, Kristin J. Rigamonti, Daniele Kleinberg, Lawrence R. Front Oncol Oncology PURPOSE: The aim of this study is to evaluate long-term treatment outcome and toxicities among vestibular schwannoma (VS) patients treated with hypofractionated stereotactic radiotherapy (HSRT). METHODS: 383 patients with unilateral VS treated with HSRT (25 Gy, five fractions) between 1995 and 2007 were retrospectively reviewed. Treatment failure was defined as requiring salvage microsurgery. Posttreatment new/progressive clinical symptoms or increases in baseline tumor volume (BTV) due to treatment effect or progression were noted. Symptom outcomes were reported as baseline and posttreatment ± improvement, respectively. Symptoms were grouped by cranial nerve (CN) VII or CNVIII. Audiometry was assessed baseline and posttreatment hearing. Patients were grouped as having greater than serviceable hearing [Gardner Robertson (GR) score 1–2] or less than non-serviceable hearing (GR score 3–5) by audiometry. RESULTS: Median follow-up was 72.0 months. Nine (2.3%) experienced treatment failure. At last follow-up, 74 (19.3%) had new/progressive symptoms and were categorized as radiologic non-responders, whereas 300 (78.3%) had no tumor progression and were grouped as radiologic responders. Average pretreatment BTV for treatment failures, radiologic non-responders, and radiologic responders was 2.11, 0.44, and 1.87 cm(3), respectively. Pretreatment CNVII and CNVIII symptoms were present in 9.4 and 93.4% of patients, respectively. Eight (24%) with pre-HSRT CNVII and 37 (10%) with pre-HSRT CNVIII symptoms recovered CN function post-HSRT. Thirty-five (9%) and 36 (9.4%) experienced new CNVII and CNVIII deficit, respectively, after HSRT. Of these, 20 (57%) and 18 (50%) recovered CNVII and CNVIII function, respectively, after HSRT. Evaluable audiograms were available in 199 patients. At baseline and at last follow-up, 65.8 and 36.2% had serviceable hearing, respectively. Fifty-one percent had preservation of serviceable hearing at last follow-up. CONCLUSION: Treatment of VS with HSRT is effective with treatment success in 97.7% and an acceptable toxicity profile. Less than one-third of patients experience any new CNVII or CNVIII deficit posttreatment. Greater than 50% of patients with serviceable hearing at baseline maintained hearing function. Improved methods to differentiate treatment effect and tumor progression are needed. Frontiers Media S.A. 2017-09-04 /pmc/articles/PMC5591320/ /pubmed/28929084 http://dx.doi.org/10.3389/fonc.2017.00200 Text en Copyright © 2017 Patel, Marciscano, Hu, Jusué-Torres, Garg, Rashid, Francis, Lim, Redmond, Rigamonti and Kleinberg. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Patel, Mira A. Marciscano, Ariel E. Hu, Chen Jusué-Torres, Ignacio Garg, Rupen Rashid, Arif Francis, Howard W. Lim, Michael Redmond, Kristin J. Rigamonti, Daniele Kleinberg, Lawrence R. Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy |
title | Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy |
title_full | Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy |
title_fullStr | Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy |
title_full_unstemmed | Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy |
title_short | Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy |
title_sort | long-term treatment response and patient outcomes for vestibular schwannoma patients treated with hypofractionated stereotactic radiotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591320/ https://www.ncbi.nlm.nih.gov/pubmed/28929084 http://dx.doi.org/10.3389/fonc.2017.00200 |
work_keys_str_mv | AT patelmiraa longtermtreatmentresponseandpatientoutcomesforvestibularschwannomapatientstreatedwithhypofractionatedstereotacticradiotherapy AT marciscanoariele longtermtreatmentresponseandpatientoutcomesforvestibularschwannomapatientstreatedwithhypofractionatedstereotacticradiotherapy AT huchen longtermtreatmentresponseandpatientoutcomesforvestibularschwannomapatientstreatedwithhypofractionatedstereotacticradiotherapy AT jusuetorresignacio longtermtreatmentresponseandpatientoutcomesforvestibularschwannomapatientstreatedwithhypofractionatedstereotacticradiotherapy AT gargrupen longtermtreatmentresponseandpatientoutcomesforvestibularschwannomapatientstreatedwithhypofractionatedstereotacticradiotherapy AT rashidarif longtermtreatmentresponseandpatientoutcomesforvestibularschwannomapatientstreatedwithhypofractionatedstereotacticradiotherapy AT francishowardw longtermtreatmentresponseandpatientoutcomesforvestibularschwannomapatientstreatedwithhypofractionatedstereotacticradiotherapy AT limmichael longtermtreatmentresponseandpatientoutcomesforvestibularschwannomapatientstreatedwithhypofractionatedstereotacticradiotherapy AT redmondkristinj longtermtreatmentresponseandpatientoutcomesforvestibularschwannomapatientstreatedwithhypofractionatedstereotacticradiotherapy AT rigamontidaniele longtermtreatmentresponseandpatientoutcomesforvestibularschwannomapatientstreatedwithhypofractionatedstereotacticradiotherapy AT kleinberglawrencer longtermtreatmentresponseandpatientoutcomesforvestibularschwannomapatientstreatedwithhypofractionatedstereotacticradiotherapy |